It is well established that CTLA4-Ig exerts its therapeutic effects in RA patients, acting on CD80/CD86 molecules on the cellular surface of antigen-presenting cells (APC) by blocking the second signal as well as licensing APC to express IDO [16, 17]. This evidence concerns the gene CTLA4 and rheumatoid arthritis.